Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1675 1676
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18257483 | COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 19329427 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | Non-Final OA | Ohio State Innovation Foundation |
| 18644750 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | Final Rejection | Ohio State Innovation Foundation |
| 18257237 | DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19 | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18294021 | NORA INHIBITORS AND METHODS OF USE | Non-Final OA | NEW YORK UNIVERSITY |
| 18836118 | PEPTIDE HAVING ANTIBACTERIAL, ANTI-INFLAMMATORY OR TISSUE REGENERATION ABILITY AND USE THEREOF | Non-Final OA | Seoul National University R&DB Foundation |
| 18571666 | A NOVEL COMPOUND ACTING AGAINST A SELECT GROUP OF BACTERIA | Non-Final OA | Northeastern University |
| 17675910 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18582271 | p53 VARIANT WITH IMPROVED LIQUID-LIQUID PHASE SEPARATION ABILITY AND ACTIVITY AND USE THEREOF | Non-Final OA | Zhejiang University |
| 17996917 | LIPID-PEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18554737 | ENGINEERING PEPTIDES FOR A A VB6 INTEGRIN BINDING AND RELATED METHODS OF USE AND SYNTHESIS | Final Rejection | Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
| 18008771 | DOCK TAG SYSTEM | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy